Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis
Open Access
- 12 September 2024
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 108, 105323
Abstract
No abstract availableKeywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Uric acid levels predict survival in men with amyotrophic lateral sclerosisJournal of Neurology, 2012
- Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional StudyInternal Medicine, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- Progression in ALS is not linear but is curvilinearJournal of Neurology, 2010
- Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress?Journal of the Neurological Sciences, 2009
- Functional monoclonal antibodies to p75 neurotrophin receptor raised in knockout miceJournal of Neuroscience Methods, 2006
- Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALSNeurology, 2006
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory functionJournal of the Neurological Sciences, 1999
- Dose-Response and Trend Analysis in EpidemiologyEpidemiology, 1995
- A Monoclonal Antibody Against Nerve Growth Factor Receptor: Immunohistochemical Analysis of Normal and Neoplastic Human TissueAmerican Journal of Clinical Pathology, 1989